Genferon light Suppositories, 10 pcs, 125000+0.005 IU+g
Directions for use and doses
The drug can be used both vaginally and rectally.
The route of administration, dose and course duration depend on age and the specific clinical situation. In adults and children over 7 years of age, Genferon Light is used in a dose of 250,000 IU of interferon alfa-2b per suppository. In children under 7 years of age, including infants, it is safe to use the drug at a dose of 125,000 IU of interferon alfa-2b per suppository. In women who are 13-40 weeks pregnant, the drug is used at a dose of 250,000 IU of interferon alfa-2b per suppository. Recommended doses and treatment regimens:
● Acute respiratory viral infections and other acute diseases of a viral nature in children: 1 suppository rectally 2 times a day with a 12-hour interval parallel to the main therapy for 5 days. If, after a 5-day treatment period, the symptoms of the disease do not decrease or become more pronounced, the patient should consult a doctor. According to clinical indications, it is possible to repeat the course of treatment after a 5-day interval.
● Acute respiratory viral infections in frequently and long-term ill children aged 3 to 6 years: 1 suppository (125,000 IU) rectally 2 times a day with an interval of 12 hours for 10 days parallel to standard therapy. After completing the main period of treatment for an acute respiratory viral infection, it is possible to switch to a prophylactic regimen: 1 suppository (125,000 IU) rectally 1 time at night, every other day for 3 weeks.
● Chronic infectious and inflammatory diseases of viral etiology in children over 7 years of age: 1 suppository (250,000 IU) rectally 2 times a day with a 12-hour interval parallel to standard therapy for 10 days. Then for 1-3 months - 1 suppository rectally at night every other day.
● Acute infectious and inflammatory diseases of the urogenital tract in children: 1 suppository rectally 2 times a day with a 12-hour interval for 10 days against the background of specific therapy prescribed and supervised by a doctor.
● Infectious and inflammatory diseases of the urogenital tract in pregnant women: 1 suppository (250,000 IU) vaginally 2 times a day with a 12-hour interval for 10 days against the background of specific therapy prescribed and supervised by a doctor.
● Infectious and inflammatory diseases of the urogenital tract in women: 1 suppository (250,000 IU) vaginally or rectally (depending on the nature of the disease) 2 times a day with a 12-hour interval for 10 days against the background of specific therapy prescribed and supervised by a doctor. For prolonged forms, 1 suppository 3 times a week, every other day, for 1-3 months.
Genferon Light suppositories 125000IU+5mg No. 10
A country
Russia
The country of production may vary depending on the batch of goods. Please check with the operator for detailed information when confirming your order.
Active substance
Interferon alpha-2b + Taurine
Compound
Interferon alpha-2b, taurine.
pharmachologic effect
Has local and systemic effects. The drug contains recombinant human interferon alpha-2b. Interferon alpha-2b has antiviral, immunomodulatory, antiproliferative and antibacterial effects. The immunomodulatory effect is manifested, first of all, by enhancing cell-mediated reactions of the immune system, which increases the effectiveness of the immune response against viruses, intracellular parasites and cells that have undergone tumor transformation. Activation under the influence of interferon of leukocytes contained in all layers of the mucous membrane ensures their active participation in the elimination of pathological foci; in addition, due to the influence of interferon, restoration of the production of secretory immunoglobulin A is achieved. The antibacterial effect is mediated by reactions of the immune system, enhanced under the influence of interferon. Taurine helps to normalize metabolic processes and tissue regeneration, has a membrane-stabilizing and immunomodulatory effect. Taurine helps maintain the biological activity of interferon, enhancing the therapeutic effect of the drug. With rectal administration of the drug, high bioavailability of interferon is observed, and therefore both local and pronounced systemic immunomodulatory effects are achieved; when used intravaginally, due to the high concentration at the site of infection and fixation on the cells of the mucous membrane, a pronounced local antiviral, antiproliferative and antibacterial effect is achieved, while the systemic effect is insignificant due to the low absorption capacity of the vaginal mucosa. The maximum concentration of interferon in the blood serum is achieved 5 hours after administration of the drug. The main route of elimination of α-interferon is renal catabolism. The half-life is 12 hours, which necessitates the use of the drug 2 times a day.
Indications for use
For the treatment of infectious and inflammatory diseases of the urogenital tract in children and women, including pregnant women. As a component of complex therapy - for the treatment of other infectious diseases of viral etiology.
Mode of application
The drug can be used both vaginally and rectally. The method of administration, dosage and course duration depend on age, the specific clinical situation and are determined by the attending physician.
Interaction
The drug is most effective as a component of complex therapy. When combined with antibacterial, fungicidal and antiviral drugs, mutual potentiation of action is observed, which makes it possible to achieve a high total therapeutic effect
Side effect
Local allergic reactions (itching and burning sensation in the vagina). These phenomena are reversible and disappear within 72 hours after cessation of administration. Continuation of treatment is possible after consultation with a doctor. Phenomena that occur when using all types of interferon alfa-2b may be observed, such as chills, fever, fatigue, loss of appetite, muscle and headaches, joint pain, sweating, as well as leukemia and thrombocytopenia. In these cases, it is recommended to consult your doctor to decide whether to discontinue the drug or reduce the dose.
Contraindications
Individual intolerance to interferon and other substances included in the drug. With caution: Exacerbation of allergic and autoimmune diseases. Use during pregnancy and lactation: Clinical studies have proven the effectiveness and safety of the drug in the second and third trimesters of pregnancy. The safety of using the drug in the first trimester of pregnancy has not been studied.
Overdose
If you accidentally administer more suppositories at a time than were prescribed by your doctor, further administration should be suspended for 24 hours, after which treatment can be resumed according to the prescribed regimen.
special instructions
The drug does not affect the performance of potentially hazardous activities that require special attention and quick reactions (driving vehicles, machinery, etc.).
Genferon light 125 thousand IU No. 10 suppositories
INSTRUCTIONS FOR MEDICAL ADMINISTRATION
GENFERON® LIGHT
Trade name of the drug:
Genferon® light
International nonproprietary name:
No
Dosage form:
vaginal and rectal suppositories
Compound
1 suppository for dosages of 125,000 IU + 5 mg, 250,000 IU + 5 mg, respectively, contains:
active ingredients:
human recombinant interferon alpha-2b (rhIFN-α2b) – 125,000 IU, 250,000 IU; taurine – 0.005 g;
Excipients:
“solid fat” - sufficient amount to obtain a suppository weighing 0.8 g, dextran 60000 - 0.00073 g, macrogol 1500 - 0.06233 g, polysorbate 80 - 0.01658 g, emulsifier T2 - 0.06630 g, sodium hydrogen citrate – 0.00005 g, citric acid – 0.00073 g, purified water – 0.03200 g.
Description
White or white with a yellowish tint, cylindrical suppositories with a pointed end are uniform in longitudinal section. An air rod or funnel-shaped depression is allowed on the cut.
Pharmacotherapeutic group:
Immunostimulants
ATX code:
L03A
Pharmacological properties
Immunobiological properties
Genferon® light
– a combination drug, the effect of which is determined by the components included in its composition. Has local and systemic effects.
The composition of the drug Genferon®
light includes recombinant human interferon alpha-2b, produced by a strain of the bacterium Escherichia coli, into which the human interferon alpha-2b gene has been introduced using genetic engineering methods.
Interferon alpha-2b has antiviral, immunomodulatory, antiproliferative and antibacterial effects. The antiviral effect is mediated by the activation of a number of intracellular enzymes that inhibit viral replication. The immunomodulatory effect is manifested, first of all, by enhancing cell-mediated reactions of the immune system, which increases the effectiveness of the immune response against viruses, intracellular parasites and cells that have undergone tumor transformation. This is achieved through the activation of CD8+ T killer cells, NK cells (natural killer cells), increased differentiation of B lymphocytes and their production of antibodies, activation of the monocyte-macrophage system and phagocytosis, as well as increased expression of molecules of the major histocompatibility complex type I, which increases the likelihood recognition of infected cells by cells of the immune system. Activation under the influence of interferon of leukocytes contained in all layers of the mucous membrane ensures their active participation in the elimination of pathological foci; in addition, due to the influence of interferon, restoration of the production of secretory immunoglobulin A is achieved. The antibacterial effect is mediated by reactions of the immune system, enhanced under the influence of interferon.
Taurine helps normalize metabolic processes and tissue regeneration, has membrane-stabilizing and immunomodulatory effects. Being a strong antioxidant, taurine directly interacts with reactive oxygen species, the excessive accumulation of which contributes to the development of pathological processes. Taurine helps maintain the biological activity of interferon, enhancing the therapeutic effect of the drug.
Pharmacokinetics
With rectal administration of the drug, high bioavailability (more than 80%) of interferon is observed, and therefore both local and pronounced systemic immunomodulatory effects are achieved; when used intravaginally, due to the high concentration at the site of infection and fixation on the cells of the mucous membrane, a pronounced local antiviral, antiproliferative and antibacterial effect is achieved, while the systemic effect is insignificant due to the low absorption capacity of the vaginal mucosa. The maximum concentration of interferon in the blood serum is achieved 5 hours after administration of the drug. The main route of excretion of α-interferon is renal catabolism. The half-life is 12 hours, which necessitates the use of the drug 2 times a day.
Indications for use
— As a component of complex therapy – for the treatment of acute respiratory viral infections and other infectious diseases of bacterial and viral etiology in children.
— As a component of complex therapy – for the treatment and prevention of repeated episodes of acute respiratory viral infections in frequently and long-term ill children aged 3 to 6 years.
— For the treatment of infectious and inflammatory diseases of the urogenital tract in children and women, including pregnant women, against the background of specific therapy prescribed and supervised by a doctor.
Contraindications
Individual intolerance to interferon and other substances included in the drug.
I trimester of pregnancy.
Carefully
Exacerbation of allergic and autoimmune diseases.
Directions for use and doses
The drug can be used both vaginally and rectally. The route of administration, dose and course duration depend on age and the specific clinical situation. In adults and children over 7 years of age, Genferon® light is used at a dose of 250,000 IU of interferon alfa-2b per suppository. In children under 7 years of age, including infants, it is safe to use the drug at a dose of 125,000 IU of interferon alfa-2b per suppository. In women who are 13-40 weeks pregnant, the drug is used at a dose of 250,000 IU of interferon alfa-2b per suppository.
Recommended doses and treatment regimens:
● Acute respiratory viral infections and other acute diseases of a viral nature in children:
1 suppository rectally 2 times a day with a 12-hour interval parallel to the main therapy for 5 days. If, after a 5-day treatment period, the symptoms of the disease do not decrease or become more pronounced, the patient should consult a doctor. According to clinical indications, it is possible to repeat the course of treatment after a 5-day interval.
● Acute respiratory viral infections in
frequently and long-term ill children aged 3 to 6 years:
1 suppository (125,000 IU) rectally 2 times a day with an interval of 12 hours for 10 days parallel to standard therapy. After completing the main period of treatment for an acute respiratory viral infection, it is possible to switch to a prophylactic regimen: 1 suppository (125,000 IU) rectally 1 time at night, every other day for 3 weeks.
● Chronic infectious and inflammatory diseases of viral etiology in children over 7 years of age:
1 suppository (250,000 IU) rectally 2 times a day at 12-hour intervals parallel to standard therapy for 10 days. Then for 1-3 months - 1 suppository rectally at night every other day.
● Acute infectious and inflammatory diseases of the urogenital tract in children:
1 suppository rectally 2 times a day with a 12-hour interval for 10 days against the background of specific therapy prescribed and supervised by a doctor.
● Infectious and inflammatory diseases of the urogenital tract in pregnant women:
1 suppository (250,000 IU) vaginally 2 times a day with a 12-hour interval for 10 days against the background of specific therapy prescribed and supervised by a doctor.
● Infectious and inflammatory diseases of the urogenital tract in women:
1 suppository (250,000 IU) vaginally or rectally (depending on the nature of the disease) 2 times a day with a 12-hour interval for 10 days against the background of specific therapy prescribed and supervised by a doctor. For prolonged forms, 1 suppository 3 times a week, every other day, for 1-3 months.
Side effect
The drug is well tolerated by patients. Very rare (frequency less than 1 in 10,000 cases): there are isolated reports of cases of allergic reactions. These phenomena are reversible and usually disappear within 72 hours after cessation of administration. Continuation of treatment is possible after consultation with a doctor.
Use during pregnancy and breastfeeding
Clinical studies have proven the effectiveness and safety of using the drug Genferon® light in women who are 13-40 weeks pregnant. Use in the first trimester of pregnancy is contraindicated.
There are no restrictions for use during lactation.
Interaction with other drugs
Genferon® light is most effective as a component of complex therapy. When combined with antibacterial, fungicidal and antiviral drugs, mutual potentiation of action is observed, which makes it possible to achieve a high total therapeutic effect.
Overdose
Cases of overdose of Genferon® light have not been registered. If you accidentally administer more suppositories at a time than were prescribed by your doctor, further administration should be suspended for 24 hours, after which treatment can be resumed according to the prescribed regimen.
special instructions
Genferon® light does not affect the performance of potentially hazardous activities that require special attention and quick reactions (driving vehicles, machinery, etc.).
Storage and transportation conditions
At temperatures from 2 to 8 °C.
Keep out of the reach of children.
Release form
Vaginal and rectal suppositories 125,000 IU+5 mg and 250,000 IU+5 mg.
5 suppositories each in a blister pack made of aluminum foil or polyvinyl chloride film. 2 blister packs along with instructions for use in a cardboard pack.
Best before date
2 years.
Do not use after the expiration date stated on the package.
Vacation conditions
Available without a prescription - vaginal and rectal suppositories 125,000 IU + 5 mg. Dispensed by prescription - vaginal and rectal suppositories 250,000 IU + 5 mg.
Registration Certificate Holder
JSC "BIOCAD", Russia, 198515, St. Petersburg, Petrodvortsovy district, Strelna village, st. Svyazi, no. 34, lit. A.
Manufacturer
JSC "BIOCAD", Russia, 143422, Moscow region, Krasnogorsk district, village. Petrovo-Dalnee.
Organization receiving consumer complaints
JSC "BIOCAD", Russia, 198515, St. Petersburg, Petrodvortsovy district, Strelna village, st. Svyazi, no. 34, lit. A.
Phone fax; e-mail: [email protected]
Send information about the development of adverse reactions to:
